½ÃÀ庸°í¼­
»óǰÄÚµå
1735857

¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼®(Á¦Ç° Á¾·ùº°, Á¾·ùº°, Åõ¿© °æ·Îº°, Áõ»óº°, Á¦Çüº°, À¯Åë ä³Îº°, Áö¿ªº°) ¹× ¿¹Ãø(2022-2032³â)

Global Lice Treatment Market Size study, by Product Type (OTC, Prescription), Type, Route of Administration, Condition, Dosage Form, Distribution Channel and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ ¾à 10¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È 6.50% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ Ä¡·áÁ¦ ½ÃÀåÀº °øÁߺ¸°Ç ¹× °³ÀÎ À§»ý¿¡ ÀÖ¾î ÇʼöÀûÀÎ ¿ä¼Ò·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ƯÈ÷ Çзɱ⠾Ƶ¿À» Áß½ÉÀ¸·Î Àü ¿¬·ÉÃþ¿¡ °ÉÃÄ ÀÌ °¨¿°¿¡ ´ëÇÑ Àνİú À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀϹÝÀǾàǰ ¹× ó¹æÀü ±â¹Ý ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϸ鼭 ±â¼ú Çõ½Å°ú Çʿ伺ÀÌ ¸ðµÎ ¿øµ¿·ÂÀÌ µÇ´Â ¹øÃ¢ÇÏ´Â ½ÃÀåÀ¸·Î ¹ßÀüÇß½À´Ï´Ù. ÀÌ ÅðÄ¡¸¦ ¸ñÇ¥·Î ÇÏ´Â Á¦Ç°µéÀº ´õ ÀÌ»ó ±âº»ÀûÀΠó¹æ¿¡ ±×Ä¡Áö ¾Ê°í, Àç°¨¿° ¹× Ä¡·á ÀúÇ×¼ºÀ» ÁÙÀ̱â À§ÇØ »ç¿ëÇϱ⠽¬¿î Àû¿ë, Ä¡·á ½Ã°£ ´ÜÃà, È¿´É °³¼± µî ¸ðµç Ãø¸é¿¡¼­ °­È­µÇ°í ÀÖ½À´Ï´Ù.

Æç¸ÞÆ®¸°À̳ª ÇÇ·¹Æ®¸°°ú °°Àº ±âÁ¸ Ä¡·áÁ¦¿¡ ´ëÇÑ ³»¼º¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö¸é¼­ ¾÷°è´Â À̹ö¸ßƾÀ̳ª ½ºÇdzë»çµå¿Í °°Àº Â÷¼¼´ë ó¹æ ¿É¼ÇÀ¸·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »õ·Î¿î ºÐÀÚ´Â È¿´ÉÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, ´õ ÀûÀº Ƚ¼ö·Îµµ Ä¡·áÇÒ ¼ö ÀÖ¾î ±âÁ¸ Ä¡·á¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ºÒ¸¸¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í ¼ÒºñÀÚ ÀÇ·á ºê·£µå ¸ðµÎ ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇÏ¿© ½ºÇÁ·¹ÀÌ¿Í Æû¿¡¼­ ·Î¼Ç°ú ¼¤Çª¿¡ À̸£±â±îÁö ´õ ³ªÀº ¼øÀÀµµ¿Í Ä¡·á È¿°ú¸¦ º¸ÀåÇÏ´Â »õ·Î¿î Àü´Þ ¸ÞÄ¿´ÏÁòÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Çб³, ¼Ò¾Æ°ú, °øÁß º¸°Ç ±â°ü¿¡¼­ ÁøÇàÇÏ´Â ÀÎ½Ä °³¼± Ä·ÆäÀÎÀº Á¶±â Ä¡·áÀÇ Á߿伺À» °­Á¶Çϸç Á¦Ç° ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

½ÅÈï °æÁ¦±¹¿¡¼­´Â ºê·£µå Á¦Ç°ÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÁö¸¸, °¡°Ý¿¡ ¹Î°¨ÇÑ ½ÃÀå¿¡¼­´Â Á¦³×¸¯ ÀǾàǰÀÌ ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ¾î ±ÕÇüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, E-CommerceÀÇ ¼ºÀåÀ¸·Î ÀÎÇØ ¼ÒºñÀÚ°¡ ´Ù¾çÇÑ ºê·£µå, °¡°Ý´ë, Á¦ÇüÀ» ¼±ÅÃÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó À̰¡ Ä¡·áÁ¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁø °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ¼ÒºñÀÚÀÇ ¿ÀÇØ, Àϰü¼º ¾ø´Â Ä¡·á, ÀϺΠÁö¿ª¿¡¼­´Â ¼ººÐ¿¡ ´ëÇÑ ±ÔÁ¦ °­È­ µîÀÇ Á¦¾à¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ °¨¿°°ú °ü·ÃµÈ »çȸÀû ³«ÀÎÀÌ ¿©ÀüÈ÷ °ø°³ÀûÀÎ Åä·ÐÀ» Á¦ÇÑÇÏ´Â ÇÑÆí, ¿Â¶óÀο¡¼­ ½ÅÁßÇÑ ±¸¸Å¸¦ À¯µµÇϰí ÀÖÀ¸¸ç, ±â¾÷µéÀº µðÁöÅÐ Àü·«À» ÃÖÀûÈ­ÇØ¾ß ÇÏ´Â »óȲ¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.

¼Ò¸Å¾÷ü¿Í Á¦Á¶¾÷ü´Â ÁøÈ­ÇÏ´Â ¼ÒºñÀÚ Çൿ¿¡ ´ëÀÀÇϱâ À§ÇØ ¿È´Ïä³Î Àü·«À» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¾à±¹ üÀÎ, ½´ÆÛ¸¶ÄÏ, E-Commerce Ç÷§ÆûÀº ÇöÀç ½Ã³ÊÁö È¿°ú¸¦ ³»¸ç °øÁ¸Çϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ ¸¶ÄÉÆÃ, ÀÎÇ÷ç¾ð¼­ ÁÖµµÀÇ ¼Ò¾Æ À§»ý ±³À°, ¸ÂÃãÇü Ä¡·á ¹øµé, ¸ÂÃãÇü Ä¡·á ¹øµé µîÀÌ ÀÌ Ä¡·áÁ¦ ºÐ¾ß¿¡¼­ ¼ÒºñÀÚ Âü¿©¸¦ À籸ÃàÇϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ Á¦Á¶¾÷üµéÀº ÇǺΰú ÀÇ»ç, ¼Ò¾Æ°ú ÀÇ»ç, Çб³ º¸°Ç Àü¹®°¡µé°ú Çù·ÂÇÏ¿© ÀÚ»ç Á¦Ç°ÀÌ ÀÇ·á±â°üÀÇ Áø·á °æ·Î¿¡ Æ÷Ç﵃ ¼ö ÀÖµµ·Ï ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ B2B2C ¿¬°è´Â ºê·£µå ½Å·Úµµ¸¦ ³ôÀ̰í Á¦Ç°ÀÇ Áö¼ÓÀûÀÎ »ç¿ëÀ» ÃËÁøÇÕ´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ ¼¼°è ÀÌ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ³ôÀº °Ç°­ ÀǽÄ, ³ôÀº ±¸¸Å·Â, OTC»Ó¸¸ ¾Æ´Ï¶ó ó¹æÀü ÆÇ¸Å¸¦ Áö¿øÇϴ źźÇÑ ÇコÄɾî ÀÎÇÁ¶ó¸¦ ¹è°æÀ¸·Î Çϰí ÀÖ½À´Ï´Ù. µ¶ÀÏ, ¿µ±¹ µîÀÇ ±¹°¡µéÀÌ ÀÌ ÅðÄ¡ ÇÁ·Î±×·¥À» Àû±ØÀûÀ¸·Î Áö¿øÇϰí ÀÖÀ¸¸ç, À¯·´ÀÌ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº µµ½Ã Àα¸ Áõ°¡, À§»ý ÀÇ½Ä Çâ»ó, ÀÇ·á ¼­ºñ½º Á¢±Ù¼º Çâ»óÀ¸·Î ÀÎÇØ À¯¸®ÇÑ ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ Àεµ¿Í µ¿³²¾Æ½Ã¾Æ¿¡¼­´Â Çö´ëÀû °Å·¡¿Í ¿Â¶óÀΠä³ÎÀ» ÅëÇÑ Á¦Ç° º¸±ÞÀÌ È°¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • Á¦Ç° Á¾·ùº°(OTC, 󹿾à)
    • Á¾·ùº°(ºê·£µå ÀǾàǰ, Á¦³×¸¯ ÀǾàǰ)
    • Åõ¿© °æ·Îº°(±¹¼Ò, °æ±¸)
    • Áõ»óº°(¸Ó¸´´Ï, ¸ö´Ï, »ç¸é¹ß´Ï)
    • Á¦Çüº°(·Î¼Ç, ¼¤Çª, Å©¸², ±âŸ)
    • À¯Åë ä³Îº°(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹)
  • ÁÖ¿ä µ¿Çâ
  • °æ±âÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð

Á¦2Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå : Á¤ÀÇ¿Í ºÐ¼® °¡Á¤

  • ºÐ¼® ¸ñÀû
  • ½ÃÀå Á¤ÀÇ
  • ºÐ¼® °¡Á¤
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ»çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚÀÇ °üÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ±â¼ú Áøº¸
      • ģȯ°æ
      • ¼ÒºñÀÚ Àǽİú ¼ö¿ë
  • ºÐ¼® ¹æ¹ý
  • ºÐ¼® ´ë»ó ±â°£
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
  • ½ÃÀå ±âȸ

Á¦4Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå : »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
    • Porter's Five Forces ¸ðµ¨·ÎÀÇ ÇâÈÄ Á¢±Ù¹ý
    • ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû ¿äÀÎ
    • °æÁ¦Àû ¿äÀÎ
    • »çȸÀû ¿äÀÎ
    • ±â¼úÀû ¿äÀÎ
    • ȯ°æÀû ¿äÀÎ
    • ¹ýÀû ¿äÀÎ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • µð½º·´¼Ç µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð

Á¦5Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç° Á¾·ùº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • OTC(Permethrin, Pyrethrin) : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • 󹿾à(Ivermectin, Spinosad, Malathion) : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)

Á¦6Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¾·ùº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ºê·£µå ÀǾàǰ : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • Á¦³×¸¯ ÀǾàǰ : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)

Á¦7Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Åõ¿© °æ·Îº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ±¹¼Ò Åõ¿© : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • °æ±¸ Åõ¿© : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)

Á¦8Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áõ»óº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ¸Ó¸´´Ï : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • ¸ö´Ï : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • »ç¸é¹ß´Ï : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)

Á¦9Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Çüº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • ·Î¼Ç : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • ¼¤Çª : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • Å©¸² : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • ±âŸ : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)

Á¦10Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Åë ä³Îº°(2022-2032³â)

  • ºÎ¹® ´ë½Ãº¸µå
  • º´¿ø ¾à±¹ : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • ¼Ò¸Å ¾à±¹ : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)
  • ¿Â¶óÀÎ ¾à±¹ : ¸ÅÃâ µ¿Ç⠺м®(2022³â¡¤2032³â)

Á¦11Àå ¼¼°èÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2022-2032³â)

  • ºÏ¹Ì ½ÃÀå
    • ¹Ì±¹ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ij³ª´ÙÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
  • À¯·´ ½ÃÀå
    • ¿µ±¹ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • µ¶ÀÏÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ÇÁ¶û½ºÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ½ºÆäÀÎÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ÀÌÅ»¸®¾ÆÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ±âŸ À¯·´ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
    • Áß±¹ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ÀεµÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ÀϺ»ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • È£ÁÖÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • Çѱ¹ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
  • ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå
    • ºê¶óÁúÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ¸ß½ÃÄÚÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå
    • »ç¿ìµð¾Æ¶óºñ¾ÆÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÌ Ä¡·áÁ¦ ½ÃÀå

Á¦12Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
    • Prestige Consumer Healthcare Inc.
    • Bayer AG
    • Johnson & Johnson Services, Inc.
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Prestige Consumer Healthcare Inc.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • Dr. Reddy's Laboratories Ltd.
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Reckitt Benckiser Group plc
    • Taro Pharmaceutical Industries Ltd.
    • Perrigo Company plc
    • Arbor Pharmaceuticals, LLC
    • Lice Clinics of America
    • Edenbridge Pharmaceuticals, LLC
    • Actavis Pharma, Inc.
    • Thornton & Ross Ltd.
    • ParaPRO LLC

Á¦13Àå ºÐ¼® ÇÁ·Î¼¼½º

  • ºÐ¼® ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ¿¹Ãø
    • °ËÁõ
    • °£Çà
  • ºÐ¼® ¼Ó¼º
ksm

Global Lice Treatment Market is valued approximately at USD 1.00 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.50% over the forecast period 2024-2032. The market for lice treatment has emerged as an essential pillar in public health and personal care, responding to the increasing awareness and prevalence of lice infestations across age groups, particularly among school-going children. The surge in demand for over-the-counter and prescription-based solutions has evolved into a thriving marketplace driven by both innovation and necessity. Products targeting lice eradication are no longer limited to basic formulations but are now being enhanced with user-friendly applications, reduced treatment time, and improved efficacy, all designed to reduce reinfestation and treatment resistance.

As concerns over resistance to traditional treatments like permethrin and pyrethrin intensify, the industry is shifting toward next-generation prescription options such as ivermectin and spinosad. These newer molecules not only improve efficacy but also require fewer applications, addressing consumer frustration with conventional treatments. Pharmaceutical companies and consumer health brands alike are investing in R&D to develop novel delivery mechanisms-ranging from sprays and foams to lotions and shampoos-ensuring better compliance and outcomes. Additionally, awareness campaigns by schools, pediatric clinics, and public health agencies are reinforcing the importance of early treatment, which in turn boosts product demand.

The increasing adoption of branded solutions in developed economies is balanced by the widespread acceptance of generics in price-sensitive markets. The market also benefits from the growth in e-commerce, which facilitates discreet access to lice treatment products, while enabling consumers to choose from a variety of brands, price points, and formulations. However, the market faces certain constraints such as consumer misconceptions, inconsistent treatment adherence, and regulatory scrutiny over ingredients in some regions. Moreover, while the social stigma associated with lice infestation continues to limit open discussion, it is also motivating discreet purchases online, pushing companies to optimize digital strategies.

Retailers and manufacturers are leveraging omnichannel strategies to cater to evolving consumer behaviors. Pharmacy chains, supermarkets, and e-commerce platforms now coexist with increasing synergy. Digital marketing, influencer-led education on pediatric hygiene, and customized treatment bundles are reshaping consumer engagement in the lice treatment space. At the same time, manufacturers are engaging with dermatologists, pediatricians, and school health professionals to ensure their products are embedded in institutional care pathways. This B2B2C alignment enhances brand credibility and recurring product use.

Regionally, North America holds a significant share of the global lice treatment market due to high health awareness, greater purchasing power, and a robust healthcare infrastructure that supports prescription as well as OTC sales. Europe follows closely, with countries such as Germany and the UK actively supporting lice control programs. The Asia Pacific region, meanwhile, is emerging as a lucrative market, fueled by growing urban populations, rising hygiene awareness, and improving access to healthcare. India and Southeast Asia, in particular, are witnessing increased product penetration through both modern trade and online channels.

Major market player included in this report are:

  • Prestige Consumer Healthcare Inc.
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Reckitt Benckiser Group plc
  • Taro Pharmaceutical Industries Ltd.
  • Perrigo Company plc
  • Arbor Pharmaceuticals, LLC
  • Lice Clinics of America
  • Edenbridge Pharmaceuticals, LLC
  • Actavis Pharma, Inc.
  • Thornton & Ross Ltd.
  • ParaPRO LLC

The detailed segments and sub-segment of the market are explained below:

By Product Type

  • OTC
    • Permethrin
    • Pyrethrin
  • Prescription
    • Ivermectin
    • Spinosad
    • Malathion

By Type

  • Branded
  • Generic

By Route of Administration

  • Topical
  • Oral

By Condition

  • Head Lice
  • Body Lice
  • Pubic Lice

By Dosage Form

  • Lotion
  • Shampoo
  • Creams
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Years considered for the study are as follows:

  • Historical year: 2022
  • Base year: 2023
  • Forecast period: 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Lice Treatment Market Executive Summary

  • 1.1. Global Lice Treatment Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Product Type (OTC; Prescription)
    • 1.3.2. By Type (Branded; Generic)
    • 1.3.3. By Route of Administration (Topical; Oral)
    • 1.3.4. By Condition (Head Lice; Body Lice; Pubic Lice)
    • 1.3.5. By Dosage Form (Lotion; Shampoo; Creams; Others)
    • 1.3.6. By Distribution Channel (Hospital Pharmacies; Retail Pharmacies; Online Pharmacies)
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Lice Treatment Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory Frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Lice Treatment Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rising awareness and school-based screening programs
    • 3.1.2. Shift to next-generation prescription therapies (ivermectin, spinosad)
    • 3.1.3. Expansion of e-commerce and omnichannel access
  • 3.2. Market Challenges
    • 3.2.1. Social stigma and treatment non-adherence
    • 3.2.2. Regulatory scrutiny over active ingredients in various regions
    • 3.2.3. Consumer misconceptions about efficacy and safety
  • 3.3. Market Opportunities
    • 3.3.1. Fastest growth in Asia-Pacific and Latin America markets
    • 3.3.2. Generic product penetration in price-sensitive segments
    • 3.3.3. Innovation in delivery formats and combination therapies

Chapter 4. Global Lice Treatment Market Industry Analysis

  • 4.1. Porter's Five Forces Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's Model
    • 4.1.7. Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economic
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top Investment Opportunities
  • 4.4. Top Winning Strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Lice Treatment Market Size & Forecasts by Product Type, 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. OTC (Permethrin; Pyrethrin) Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 5.3. Prescription (Ivermectin; Spinosad; Malathion) Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 6. Global Lice Treatment Market Size & Forecasts by Type, 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Branded Products Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 6.3. Generic Products Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 7. Global Lice Treatment Market Size & Forecasts by Route of Administration, 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Topical Administration Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 7.3. Oral Administration Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 8. Global Lice Treatment Market Size & Forecasts by Condition, 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Head Lice Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 8.3. Body Lice Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 8.4. Pubic Lice Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 9. Global Lice Treatment Market Size & Forecasts by Dosage Form, 2022-2032

  • 9.1. Segment Dashboard
  • 9.2. Lotion Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 9.3. Shampoo Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 9.4. Creams Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 9.5. Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 10. Global Lice Treatment Market Size & Forecasts by Distribution Channel, 2022-2032

  • 10.1. Segment Dashboard
  • 10.2. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 10.3. Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
  • 10.4. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

Chapter 11. Global Lice Treatment Market Size & Forecasts by Region, 2022-2032

  • 11.1. North America Market
    • 11.1.1. U.S. Lice Treatment Market
    • 11.1.2. Canada Lice Treatment Market
  • 11.2. Europe Market
    • 11.2.1. UK Lice Treatment Market
    • 11.2.2. Germany Lice Treatment Market
    • 11.2.3. France Lice Treatment Market
    • 11.2.4. Spain Lice Treatment Market
    • 11.2.5. Italy Lice Treatment Market
    • 11.2.6. Rest of Europe Lice Treatment Market
  • 11.3. Asia Pacific Market
    • 11.3.1. China Lice Treatment Market
    • 11.3.2. India Lice Treatment Market
    • 11.3.3. Japan Lice Treatment Market
    • 11.3.4. Australia Lice Treatment Market
    • 11.3.5. South Korea Lice Treatment Market
    • 11.3.6. Rest of Asia Pacific Lice Treatment Market
  • 11.4. Latin America Market
    • 11.4.1. Brazil Lice Treatment Market
    • 11.4.2. Mexico Lice Treatment Market
    • 11.4.3. Rest of Latin America Lice Treatment Market
  • 11.5. Middle East & Africa Market
    • 11.5.1. Saudi Arabia Lice Treatment Market
    • 11.5.2. South Africa Lice Treatment Market
    • 11.5.3. Rest of Middle East & Africa Lice Treatment Market

Chapter 12. Competitive Intelligence

  • 12.1. Key Company SWOT Analysis
    • 12.1.1. Prestige Consumer Healthcare Inc.
    • 12.1.2. Bayer AG
    • 12.1.3. Johnson & Johnson Services, Inc.
  • 12.2. Top Market Strategies
  • 12.3. Company Profiles
    • 12.3.1. Prestige Consumer Healthcare Inc.
      • 12.3.1.1. Key Information
      • 12.3.1.2. Overview
      • 12.3.1.3. Financial (Subject to Data Availability)
      • 12.3.1.4. Product Summary
      • 12.3.1.5. Market Strategies
    • 12.3.2. Dr. Reddy's Laboratories Ltd.
    • 12.3.3. Sanofi S.A.
    • 12.3.4. Teva Pharmaceutical Industries Ltd.
    • 12.3.5. Reckitt Benckiser Group plc
    • 12.3.6. Taro Pharmaceutical Industries Ltd.
    • 12.3.7. Perrigo Company plc
    • 12.3.8. Arbor Pharmaceuticals, LLC
    • 12.3.9. Lice Clinics of America
    • 12.3.10. Edenbridge Pharmaceuticals, LLC
    • 12.3.11. Actavis Pharma, Inc.
    • 12.3.12. Thornton & Ross Ltd.
    • 12.3.13. ParaPRO LLC

Chapter 13. Research Process

  • 13.1. Research Process
    • 13.1.1. Data Mining
    • 13.1.2. Analysis
    • 13.1.3. Market Estimation
    • 13.1.4. Validation
    • 13.1.5. Publishing
  • 13.2. Research Attributes
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦